RAD51C‐deficient cancer cells were more sensitive to olaparib than were RAD51C‐proficient cancer cells, and the silencing of RAD51C in olaparib‐resistant cell lines could enhance olaparib sensitivity. Here, RAD51C is linked to cancer.